Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
≥98% PuritySupplier batch spec · ≥98% (class spec)
GLP-1 and Incretin Research PeptidesSKU: CP-RC10
Retatrutide + Cagrilintide Blend 10mg
≥98% PuritySupplier batch spec; selected lots Janoshik-tested
€80.99In Stock
Delivers to EU in 11-14 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Research-grade Retatrutide + Cagrilintide Blend. ≥ 98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
Volume PricingApplied automatically at checkout
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €80.99 | €80.99 | -- |
| 3+ | €76.94 | €230.82 | 5% off |
| 5+Most Popular | €72.89 | €364.45 | 10% off |
| 10+ | €68.84 | €688.42 | 15% off |
1
Total: €80.99
Free shipping on orders over €200
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Purity HPLC
99.3% average HPLC purity, verified by independent third-party testing
Third-Party Tested
Janoshik report published when available
Fast Shipping
24h dispatch, EU-wide shipping from €4.99
Third-Party Tested
Supplier batch specification on every product; independent Janoshik report on selected lots
Last reviewed: 2026-06-10
About Retatrutide + Cagrilintide Blend 10mg
Important Notice — Research Use Only
For laboratory research purposes only. Not for human consumption. Retatrutide + Cagrilintide Blend is supplied by CertaPeptides strictly as a research compound for in vitro and preclinical research use. Clinical trial figures cited below are taken from peer-reviewed publications and reported here for research context only. They are not claims about what CertaPeptides' research material will do in any individual. This product is not a drug, not a dietary supplement, and is not approved by the FDA, EMA, or any regulatory authority for therapeutic use.
Retatrutide + Cagrilintide Blend combines two peptide research compounds studied in clinical development for metabolic research: Retatrutide (LY3437943), a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly, and Cagrilintide, a long-acting amylin analogue developed by Novo Nordisk. Each vial contains 5mg of each peptide (10mg total). This blend allows in vitro and preclinical study of metabolic regulation through two distinct but complementary hormonal systems — gut incretins versus pancreatic amylin receptor signalling.
Retatrutide's triple agonism is its defining pharmacological characteristic. GLP-1 receptor activation modulates insulin secretion and satiety signalling in research models; GIP receptor activation affects insulin sensitivity and lipid metabolism parameters in research models; glucagon receptor activation increases energy expenditure readouts in preclinical assays. For research context: Jastreboff et al. (2023) reported, in a Phase 2, 48-week, placebo-controlled trial of 338 adults with obesity, a mean percent change in body weight of −24.2% in the retatrutide 12mg group versus −2.1% in placebo. These figures are from a specific clinical trial population and are not claims about what this research compound will produce. Source: New England Journal of Medicine, 2023;389(6):514–526. PMID 37366315.
Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. In research models, amylin is studied for its role in slowing gastric emptying, reducing postprandial glucagon, and central satiety signalling distinct from GLP-1 signalling. Cagrilintide's long half-life (approximately 7 days) is a characteristic relevant to study design in preclinical research protocols. For research context: Novo Nordisk Phase 2 data showed Cagrilintide produced approximately 8% mean body weight change as monotherapy; combination data with semaglutide (CagriSema) showed greater changes than either alone. These are reported figures from specific trial populations for research context only.
Specifications
| Parameter | Value |
|---|---|
| Component 1 | Retatrutide 5mg (GLP-1/GIP/glucagon triple agonist) |
| Component 2 | Cagrilintide 5mg (long-acting amylin analogue) |
| Total per Vial | 10mg combined |
| Purity | ≥98% (supplier batch spec; 99.3% avg across independently tested lots, each component) |
| Format | Lyophilized powder, single-use vial |
| Storage | -20°C before reconstitution; 2-8°C after |
Storage
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution. Use within 28 days of reconstitution. Both peptides are stable under proper storage conditions.
Why combine a triple incretin agonist with an amylin analogue in research?
Retatrutide targets the incretin system (GLP-1, GIP, glucagon receptors) while Cagrilintide targets amylin receptor signalling — two distinct hormonal pathways that independently regulate appetite, satiety, and metabolic parameters in research models. The research rationale for combining them is that they produce complementary effects through different mechanisms: Retatrutide modulates incretin-driven insulin secretion and energy expenditure readouts; Cagrilintide is studied for postprandial satiety and gastric emptying through amylin-mediated pathways in model systems. CagriSema (a semaglutide + cagrilintide combination studied by Novo Nordisk) provided clinical-trial evidence that multi-pathway incretin + amylin combinations produce different metabolic profiles than single-pathway approaches in the specific trial populations studied. These outcomes are reported for research context only and do not describe what this research compound will produce in any individual.
What is Retatrutide's status in clinical development?
Retatrutide (LY3437943) is in active Phase III clinical development by Eli Lilly. Phase II data published in Jastreboff et al. (2023, NEJM 389:514-526, PMID 37366315) reported approximately 24% mean body weight change at 48 weeks in the 12mg group in the adults with obesity studied, with dose-dependent effects consistent with the triple-agonism mechanism. It has not received regulatory approval. As a research compound, it allows preclinical and mechanistic study of GLP-1/GIP/glucagon co-agonism. For research purposes only. Not for human consumption.
What makes Cagrilintide different from native amylin?
Native amylin has a very short half-life and propensity for aggregation (amyloid formation), which limits its research utility in longer-duration protocols. Cagrilintide is a long-acting amylin analogue engineered for stability and extended duration — approximately 7-day half-life, a characteristic relevant to study design in preclinical research protocols. In research models it retains amylin's core biological actions: slowing gastric emptying, reducing postprandial glucagon, and activating central satiety pathways through amylin receptors in the hypothalamus and area postrema. These properties are complementary to GLP-1 receptor agonism in receptor-pharmacology research models, which is why the combination approach is being studied in research. All referenced effects are from published research and do not constitute claims about this research compound's activity in any individual.
Retatrutide + Cagrilintide Blend is supplied for laboratory research use only. Not approved for human use. Not for human consumption. Handle in compliance with institutional biosafety guidelines. All clinical trial figures cited are from peer-reviewed publications and are reported for research context only.
Specification Summary
Purity99.3% avg
FormLyophilized Powder
Storage-20\u00B0C
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, TCE Worldwide for all cross-border EU and non-EU markets (UK, Switzerland, Norway, Iceland, Israel, Serbia). Delivery 1–14 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
Frequently Asked
Research Library
Related Research Articles
Based on category & popularity
Researchers Also Studied
SAME FIELDGLP-1 and Incretin Research Peptides
Retatrutide Research Starter Kit
Retatrutide 10mg + Bacteriostatic Water 5ml + 2 x 3ml syringes + 5 x 1ml insulin syringes. Everything you need to begin research. For research purposes only. Bundle price: save EUR 27.47 vs buying the peptide, bacteriostatic water and syringe packs separately (about EUR 106.46 on their own).
€78.99
SAME FIELDGLP-1 and Incretin Research Peptides
Tirzepatide Research Starter Kit
Tirzepatide 10mg + Bacteriostatic Water 5ml + 2 x 3ml syringes + 5 x 1ml insulin syringes. Everything you need to begin research. For research purposes only. Bundle price: save EUR 25.97 vs buying the peptide, bacteriostatic water and syringe packs separately (about EUR 79.96 on their own).
€53.99
SAME FIELDGLP-1 and Incretin Research Peptides
Liraglutide
Research-grade Liraglutide. ≥98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
From€43.99
SAME FIELDGLP-1 and Incretin Research Peptides
Retatrutide
Retatrutide is a novel triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. This multi-receptor approach has generated significant research interest in metabolic studies. Triple hormone receptor agonism (GIP/GLP-1/Glucagon) Metabolic pathway modulation research Energy homeostasis and body composition studies For research purposes only.
From€44.49
Frequently researched together
Retatrutide + Cagrilintide Blend 10mg€80.99
1